Save Up To 70% with generic medications and up to 40% with brand name drugs. Get FREE WorldWide shipping on $149 or more...
Ovarian Cancer » Oral COTI-2 Plus Doxil(R) Is Superior...
Home » News » Oral COTI-2 Plus Doxil(R) Is Superior To...
Oral COTI-2 Plus Doxil(R) Is Superior To Doxil Alone In An Animal Model Of Human Ovarian Cancer
Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced important positive results today from a series of experiments carried out at a prominent American cancer research facility.
Read full article @ MedicalNewsToday
Read Also Other "Ovarian Cancer" News
-
Platypus Link To Ovarian Cancer
Researchers from the Royal Adelaide Hospital and University of Adelaide...
